AstraZeneca targets severe COVID-19 patients for antibody therapy despite Regeneron, Lilly setbacks

AstraZeneca has talked up the prospects of its anti-SARS-CoV-2 antibody working in severe COVID-19 patients despite rival assets from Eli Lilly and Regeneron failing in that population. Mene Pangalos, Ph.D., an AstraZeneca executive vice president, made the comments while sharing news the antibody is set to start a prophylaxis study next week.